During the past decade, Sarah Cannon Research Institute conducted 344 clinical trials. In the 10-year time frame, 344 clinical trials started and 120 clinical trials were completed, i.e. on average, 34.9% percent of trials that started reached the finish line to date. In the past 5 years, 127 clinical trials started and 68 clinical trials were completed. i.e. 53.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sarah Cannon Research Institute" #1 sponsor was "Hoffmann-La Roche" with 35 trials, followed by "Genentech, Inc." with 34 trials sponsored, "Pfizer" with 34 trials sponsored, "Eli Lilly and Company" with 24 trials sponsored and "Celgene" with 24 trials sponsored. Other sponsors include 425 different institutions and companies that sponsored additional 212 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sarah Cannon Research Institute" #1 collaborator was "Merck Sharp & Dohme LLC" with 16 trials as a collaborator, "AstraZeneca" with 8 trials as a collaborator, "Genentech, Inc." with 7 trials as a collaborator, "National Cancer Institute (NCI)" with 7 trials as a collaborator and "Bristol-Myers Squibb" with 6 trials as a collaborator. Other collaborators include 103 different institutions and companies that were collaborators in the rest 78 trials.

According to Clinical.Site data, the most researched conditions in "Sarah Cannon Research Institute" are "Breast Cancer" (38 trials), "Ovarian Cancer" (37 trials), "Multiple Myeloma" (30 trials), "Advanced Solid Tumors" (24 trials) and "Colorectal Cancer" (23 trials). Many other conditions were trialed in "Sarah Cannon Research Institute" in a lesser frequency.

Most popular intervention types in "Sarah Cannon Research Institute" are "Drug" (519 trials), "Biological" (77 trials), "Other" (16 trials), "Combination Product" (5 trials) and "Genetic" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (42 trials), "Atezolizumab" (30 trials), "Pembrolizumab" (30 trials), "Gemcitabine" (24 trials) and "Paclitaxel" (22 trials). Other intervention names were less common.

The vast majority of trials in "Sarah Cannon Research Institute" are 527 trials for "All" genders, 43 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are NaN active trials in "Sarah Cannon Research Institute". 1 are not yet recruiting, 122 are recruiting, 96 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 268 completed trials in Sarah Cannon Research Institute, 1 suspended trials, and 78 terminated clinical trials to date.

Out of the total trials that were conducted in Sarah Cannon Research Institute, 350 "Phase 1" clinical trials were conducted, 205 "Phase 2" clinical trials and 98 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 2 trials that are defined as “Not Applicable".

Sarah Cannon Research Institute has several departments that took part in Clinical trials: "Sarah Cannon Cancer Center" - 232 trials, "Sarah Cannon Research Institute at Tennessee Oncology" - 60 trials, "Sarah Cannon Research Institute" - 14 trials, "The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers" - 9 trials, "Sarah Cannon-Minnie Pearl Cancer Center" - 9 trials, "Sarah Cannon/Colorado Blood Cancer Institute" - 7 trials, "Sarah Cannon Research Institute at Florida Cancer Specialists" - 6 trials